News Posts List
Some of world's leading experts address UK patients
04/25/2010
World experts in the treatment of kidney cancer will gather in London 06 May 2010 to discuss cutting-edge treatments with patients and their family members. Also on the expert panel, a barrister who handles patient appeals to NICE. Travel subsidies for the indigent living in Europe are available. See "Calendar of Events" at http://kidneycancer.org for details.
Welsh nurses receive lesson in cancer care
04/25/2010
This informative all-day meeting gave over 40 nurses from across Wales the opportunity to learn more about kidney cancer and improve patient care and their understanding of the disease.
First European Kidney Cancer Nursing Conference Agenda
04/25/2010
07 May 2010, London. View the agenda or register here: http://www.kidneycancer.org/knowledge/learn/medical-education-programs.
Dunk tank fundraiser to benefit Kidney Cancer Association
04/24/2010
Penn State Football Uplifting Athletes has announced that nine current players will be participating in a dunk tank fundraiser from 5-7 p.m. on Friday (April 23) near Beaver Stadium as part of Blue-White Weekend presented by AAA.
A prospective study of one-carbon metabolism biomarkers and risk of renal cell carcinoma
04/24/2010
Previous studies have found associations between one-carbon metabolism factors and risk of several cancers, but little is known regarding renal cell carcinoma (RCC). We conducted a nested casecontrol study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, a prospective study of Finnish male smokers aged 5069 at baseline.
Renal Cell (Kidney) Cancer Forum & Blog
04/24/2010
Ask Dr. Anthony Ciarallo a Question Regarding Adult Renal Cell (Kidney) Cancer [forum section]
Tumors Deficient in a Specific Enzyme Are Sensitive to a New Drug 'ADI-PEG 20'
04/22/2010
He et al also established primary renal cell carcinoma cultures from fresh human tumor biopsies which were ASS-deficient. ADI-PEG 20 inhibited growth of these cells. These findings suggest that ASS deficiency may serve as a biomarker for selecting tumors for targeted therapy with ADI-PEG 20.
Seattle Genetics Highlights ADC and SEA Technologies at AACR
04/22/2010
These findings illustrate the mechanism for the release of cysteine-mcMMAF after internalization of the ADC into target cells (Abstract #5334). SGN-75 is in an ongoing phase I clinical trial for CD70-positive relapsed/refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma.
Renal Cell Carcinoma Mortality Calculator
04/22/2010
Is it a tool or a toy? You can decide. Bear in mind, no two cases are exactly alike.
MethylGene Presents Preclinical Data for MGCD265 (A Multi-Targeted Met Kinase Inhibitor) at the American Association for Cancer Research (AACR) Annual Meeting
04/21/2010
MGCD265 is an oral multi-targeted receptor tyrosine kinase inhibitor currently in multiple clinical trials. MGCD265 targets Met and blocks Met activities which contribute to cancer development and progression such as cell proliferation, motility, angiogenesis and tumor cell survival.
News Feed